Baidu
map

Chest:他汀对脓毒症的药物特异性影响与其降脂效力有关系吗?

2017-12-26 吴星 环球医学

2017年9月,发表在《Chest》的一项由台湾、意大利和美国科学家进行的基于人群的队列研究,考察了他汀对脓毒症结局的药物特异性影响。

2017年9月,发表在《Chest》的一项由台湾、意大利和美国科学家进行的基于人群的队列研究,考察了他汀对脓毒症结局的药物特异性影响。

背景:经过最近实验研究证实的他汀治疗是否具有抗菌活性,在脓毒症中发挥药物或类别特异性作用仍然未知。

方法:使用国家健康保险研究数据库的数据,分析了脓毒症患者的短期死亡率。他汀使用的定义为指数脓毒症住院前,具体他汀(阿托伐他汀、辛伐他汀或瑞舒伐他汀)累积使用>30天。研究者通过多变量调整Cox模型,和1:1:1的倾向得分(PS)匹配技术进行的匹配分析,确定了他汀和脓毒症结局之间的相关性。

结果:总共52737例脓毒症患者满足入组标准,其中的1855例服用阿托伐他汀,916例服用辛伐他汀,732例服用瑞舒伐他汀。与不使用者相比,辛伐他汀(HR,0.72;95% CI,0.58~0.90)和阿托伐他汀(HR,0.78;95% CI,0.68~0.90)与30天生存率的改善相关,而瑞舒伐他汀并非如此(HR,0.87;95% CI,0.73~1.04)。使用瑞舒伐他汀作为参考,阿托伐他汀(HR,0.79;95% CI,0.64~0.99)和辛伐他汀(HR,0.77;95% CI,0.59~0.99)在预防死亡上具有优越的有效性。

结论:与体外实验结果相一致,结果表明,他汀对脓毒症的药物特异性影响与其降脂效力不相关。

原始出处:

Lee CC, Lee MG, Hsu TC, et al. A Population-Based Cohort Study on the Drug-Specific Effect of Statins on Sepsis Outcome. Chest. 2017 Sep 27. pii: S0012-3692(17)32803-9. doi: 10.1016/j.chest.2017.09.024.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929454, encodeId=1e3a192945460, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jan 25 05:56:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899182, encodeId=6f751899182d2, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Mar 04 10:56:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274128, encodeId=17a12e4128f4, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Dec 31 10:21:50 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051018, encodeId=df9b205101833, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Oct 29 03:56:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
    2018-01-25 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929454, encodeId=1e3a192945460, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jan 25 05:56:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899182, encodeId=6f751899182d2, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Mar 04 10:56:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274128, encodeId=17a12e4128f4, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Dec 31 10:21:50 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051018, encodeId=df9b205101833, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Oct 29 03:56:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929454, encodeId=1e3a192945460, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jan 25 05:56:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899182, encodeId=6f751899182d2, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Mar 04 10:56:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274128, encodeId=17a12e4128f4, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Dec 31 10:21:50 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051018, encodeId=df9b205101833, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Oct 29 03:56:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
    2017-12-31 1dd8c52fm63(暂无匿称)

    学习学习.继续关注

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1929454, encodeId=1e3a192945460, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jan 25 05:56:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899182, encodeId=6f751899182d2, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Mar 04 10:56:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274128, encodeId=17a12e4128f4, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Dec 31 10:21:50 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051018, encodeId=df9b205101833, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Oct 29 03:56:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]

相关资讯

Intens Care Med:血管加压素治疗脓毒症和血管扩张性休克时不同血压目标值的比较分析!

由此可见,更高的目标血压可能会增加采用加压素治疗超过6小时患者的死亡率。在任何亚组中,较低的血压目标与患者重要的不良事件无关,包括慢性高血压患者。

Lancet respir med:在救护车上即开始输注抗生素是否可改善脓毒症患者的预后?

急诊医疗(EMS)的医务人员为改善与时间相关的疾病(如创伤和心肌梗死)的预后做出重大贡献。脓毒症患者是否也可从及时的院前医疗中获益,Nedia Alam等人对此在多个中心进行一项非盲的随机试验,评估在救护车上进行常规护理的基础上,早期予以抗生素的效果。对EMS人员进行培训,如何诊断脓毒症。将符合要求的患者随机(1:1)分至干预组(常规护理+头孢曲松钠 2000mg 静滴)或常规护理组。并根据地域分

Intensive Care Med:多层面教育干预的抗感染措施对脓毒症死亡率有无影响?

发表在《Intensive Care Med》的一项由德国、瑞士、加拿大等国科学家进行的群随机试验,考察了抗感染措施多层面教育干预对脓毒症死亡率的影响。

JAHA:房颤和脓毒症患者抗凝治疗的出血并发症!

在败血症诊断时服用华法林治疗的AF患者在脓毒症后3个月内出血率增加。华法林的使用与死亡率较低相关,尽管血栓栓塞率几乎相当。

Anesth Analg:血管内皮细胞糖萼结构状态与脓毒症小鼠病理状态相关

内皮表层(ESL)调节血管通透性维持血流动力学稳定。糖萼(GCX)是一种复杂而脆弱的超微结构,是内皮表层(ESL)的重要组成部分。糖萼(GCX)的异常被认为可触发病理性渗透增加。在本实验中,我们对重要器官中糖萼(GCX)的形态和功能特性进行综合分析。

Crit care med:脓毒症使用肾脏替代治疗的效果如何?

目前,脓毒症患者的急性肾脏替代治疗急剧增加,医疗成本大幅增加。然而,各医院使用的差异以及良好的使用效果是否与更好的结果有关尚不得而知。近期,一项发表在杂志Crit care med上的研究进行了回顾性队列分析,对2011年全国18岁以上的脓毒症和急性肾损伤的住院病人进行了抽样检测。此项研究估计了每家医院的脓毒症和急性肾损伤患者使用急性肾脏替代治疗的风险和可靠性调整率。在调整了患者和医院特征后,研究

Baidu
map
Baidu
map
Baidu
map